1. Home
  2. CHRO

as 05-24-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.

Founded: 2002 Country:
United States
United States
Employees: N/A City: NORTH BRUNSWICK
Market Cap: 8.3M IPO Year: 2024
Target Price: N/A AVG Volume (30 days): 25.0K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -7.03 EPS Growth: N/A
52 Week Low/High: $1.21 - $6.00 Next Earning Date: 05-15-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Stock Insider Trading Activity of Chromocell Therapeutics Corporation (CHRO)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Friedberg Ezra M CHRO Director Feb 21 '24 Buy $6.00 16,667 $100,002.00 545,721 SEC Form 4

Share on Social Networks: